Study for development of new treatment for antibody mediated rejection in organ transplantatio
Not Applicable
Recruiting
- Conditions
- organ failure
- Registration Number
- JPRN-UMIN000030525
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with active infections, or malignancy, or patients whom the responsible person decided to be not appropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms are being explored in JPRN-UMIN000030525 for treating antibody mediated rejection in organ transplantation?
How does the experimental treatment in JPRN-UMIN000030525 compare to standard-of-care therapies for antibody mediated rejection in organ transplantation?
What biomarkers are used in JPRN-UMIN000030525 to identify patients at high risk for antibody mediated rejection in organ transplantation?
What are the known or potential adverse events associated with the new treatment approach in JPRN-UMIN000030525 for antibody mediated rejection?
Are there any related compounds or combination therapies being investigated alongside the intervention in JPRN-UMIN000030525 for treating antibody mediated rejection in organ transplantation?